Kura Oncology logo
Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.60
+0.08 (0.76%)
At close: Oct 9, 2026, 4:00 PM EDT
10.61
+0.01 (0.09%)
After-hours: Oct 9, 2026, 7:30 PM EDT

Company Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

The company is headquartered in San Diego, California.

Kura Oncology, Inc.
Kura Oncology logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees260
CEOTroy Wilson

Contact Details

Address:
4930 Directors Place, Suite 500
San Diego, California 92121
United States
Phone858 500 8800
Websitekuraoncology.com

Stock Details

Ticker SymbolKURA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001422143
CUSIP Number50127T109
ISIN NumberUS50127T1097
Employer ID61-1547851
SIC Code2834

Key Executives

NamePosition
Dr. Troy Edward Wilson J.D., Ph.D.Chairman, Chief Executive Officer and President
Kathleen FordChief Operating Officer
Brian T. Powl M.B.A., M.S.Chief Commercial Officer
Jennifer FulkChief Financial Officer
Thomas DoyleSenior Vice President of Finance and Accounting
Dr. Francis J. Burrows Ph.D.Chief Scientific Officer
Greg MannSenior Vice President of Investor Relations and Corporate Affairs
Teresa Brophy Bair Esq., J.D.Chief Legal Officer and Corporate Secretary
Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing and Supply Chain
Dr. Mollie Leoni M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Sep 29, 2026144Filing
Sep 29, 2026144Filing
Sep 29, 2026144Filing
Sep 28, 2026144Filing
Sep 28, 2026144Filing
Sep 28, 2026144Filing
Sep 28, 2026144Filing
Sep 28, 2026144Filing
Sep 28, 2026144Filing
Sep 24, 2026144Filing